Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
CONCLUSIONS: The use of ombitasvir, paritaprevir, and ritonavir for treatment of HCV-infected patients with advanced renal disease was safe and effective, moreover, it was associated with significantly improved eGFR.
PMID: 30791838 [PubMed - in process]
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
More News: Anemia | Blood Transusion | Chronic Kidney Disease | Cirrhosis | Diabetes | Egypt Health | Endocrinology | Gastroenterology | Hepatitis | Hepatitis C | Hypertension | Laboratory Medicine | Liver | Norvir | Study | Urology & Nephrology